Samples from tissue microarrays of 552 NSCLC patients were analyzed to measure the levels of 3 different tumor-infiltrating lymphocytes (TILs): CD3, CD8, and CD20. An elevated level of CD3 or CD8 was associated with longer survival.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
March 12, 2015
Aerogenous Metastases: A Potential Game Changer in the Diagnosis and Management of Primary Lung Adenocarcinoma
December 10, 2014
This interesting article summarizes the evidence from clinical, radiologic and pathologic investigations that lung cancer, specifically adenocarcinoma, may metastasize through the airways, defined as discontinuous spread of cancer cells from the primary tumor through the airways to adjacent or distant lung parenchyma.
Identification of Independent Primary Tumors and Intrapulmonary Metastases Using DNA Rearrangements in Non-Small-Cell Lung Cancer
November 11, 2014
Differentiating a primary lung cancer from an intrapulmonary metastasis can be challenging. The authors developed a lineage test using whole genome amplification and next-generation sequencing to identify breakpoints in known primary tumors and known metastases. Independent primary tumors did not share any genomic rearrangements, whereas primary tu
Phase II Study of Accelerated Hypofractionated Three-Dimensional Conformal Radiotherapy for Stage T1-3 N0 M0 Non–Small Cell Lung Cancer: NCIC CTG BR.25
September 12, 2014
This multi-institutional phase II trial (80 patients from 17 Canadian institutions) was performed to assess if a hypofractionated accelerated radiotherapy regimen for cytohistological-proven early stage NSCLC (peripherally located T1 to T3 N0 M0) has a good local control rate.
August 15, 2014
This retrospective study involving 7 institutions evaluated the utility of PET for mediastinal staging in patients who had undergone resection of pulmlonary carcinoid tumors and nodal dissection. 88% of pts had typical carcinoid tumors. The sensitivity of PET was only 33%, whereas the specificity was 94%.
Impact of Brachytherapy on Local Recurrence Rates After Sublobar Resection: Results From ACOSOG Z4032 (Alliance), a Phase III Randomized Trial for High-Risk Operable Non–Small-Cell Lung Cancer
August 9, 2014
This multiinstitutional randomized trial compared sublobar resection alone to sublobar resection with adjuvant brachytherapy in high risk patients with peripheral NSCLC <3cm. Time to and type of local recurrence were similar between the groups. Brachytherapy did not importantly improve local control in patients with potentially compromised margi
Recurrence and Survival Outcomes After Anatomic Segmentectomy Versus Lobectomy for Clinical Stage I Non–Small-Cell Lung Cancer: A Propensity-Matched Analysis
August 9, 2014
This single-institution retrospective study used propensity score matching to compare long-term outcomes of anatomic segmentectomy vs lobectomy for early stage non-small cell lung cancer. A total of 312 pts were matched in each group. Locoregional and overall recurrence rates were similar between the groups. Freedom from recurrence (70% for segme
July 4, 2014
To illustrate the potential need for regional quality improvement efforts in thoracic surgery, the authors conducted a study of lung resection in Washington state using a discharge database including nearly 8,500 pts over a 12-year period. Inpatient mortality decreased over time but there was no change in the incidence of prolonged length of stay.
Low-dose computed tomography lung cancer screening in the Medicare program: Projected clinical, resource, and budget impact.
June 25, 2014
In this study presented by Dr. Joshua A. Roth recently at the ASCO meeting, they used a model to forecast the 5-year results of implementation of a screening program (as suggest the NLST, age older than 55 with at least 30 pack-years of smoking history) in comparison to no screening program.
May 9, 2014
Using the Nationwide Inpatient Sample, the authors evaluated outcomes and costs of VATS (37,595) vs robotic (2,498) lobectomy 2008-2011. Robotic lobectomy was associated with higher rates of complications, particularly cardiovascular and iatrogenic bleeding, and higher costs ($22,582 vs $17,874).